Antivenom Market Report 2026

Antivenom Market Overview

• Antivenom market size has reached to $2.04 billion in 2025 • Expected to grow to $2.91 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Number Of Snake Bites To Drive Market Growth • Market Trend: Advancements in Antivenom Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antivenom Market?

Antivenom, also known as antivenin, is an antibody therapy that can block the poisons inside a specific venom if injected soon after a bite. It is generally used to treat poisonous animal bites or stings, such as rattlesnakes, moccasins, and copperheads. The main types of antivenom include monovalent, polyvalent, and others. Monovalent antivenom is a formulation of antivenom that is specifically made to combat the effects of a single species of snake venom or a particular toxin. They are used to treat antivenoms produced by various animals, including snakes, scorpions, spiders, and others, and are operated through various modes of action, including cytotoxic, neurotoxic, hemotoxic, cardiotoxic, myotoxic, and others. These are used by various end-users, such as hospitals, clinics, ambulatory surgical centers, and others.

What Is The Antivenom Market Growth Forecast?

The antivenom market size is expected to see strong growth in the next few years. It will grow to $2.91 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancements in recombinant technologies, increasing government funding for antivenom programs, growing prevalence of exotic pet ownership, expansion of healthcare infrastructure in emerging markets, adoption of precision medicine approaches. Major trends in the forecast period include recombinant antivenom development, cold chain optimization for antivenoms, rapid diagnostic tools for venom identification, expansion of regional antivenom production, personalized antivenom therapy.

Global Antivenom Market Segmentation

1) By Type: Monovalent, Polyvalent, Other Types 2) By Animal: Snakes, Scorpions, Spiders, Other Animals 3) By Mode of Action: Cytotoxic, Neurotoxic, Hemotoxic, Cardiotoxic, Myotoxic, Other Modes Of Action 4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Monovalent: Specific Antivenoms For Individual Snake Species, Specific Antivenoms For Individual Venom Types 2) By Polyvalent: Broad-Spectrum Antivenoms, Regional Polyvalent Antivenoms 3) By Other Types: Antivenoms For Other Venoms, Recombinant Antivenoms, Antivenom For Rare Venoms

What Is The Driver Of The Antivenom Market?

The growing incidence of snake bites is expected to propel the growth of the antivenom market going forward. Snake bites are injuries that can lead to a potentially fatal disease caused by toxins in a venomous snake's bite. Antivenom is a specialized treatment that, when taken early and in an adequate therapeutic dose, can potentially prevent or reverse most of the symptoms of snakebite envenoming. For instance, in September 2023, according to the highlights shared by the World Health Organization (WHO), a Switzerland-based United Nations organization responsible for public health, an estimated 5.4 million people globally are bitten by snakes each year, resulting in 1.8 to 2.7 million cases of envenoming. Each year, approximately 81,410 to 137,880 individuals die as a result of snake bites. This strategy aims to achieve a 50% reduction in mortality and disability caused by snakebite envenoming by the year 2030. Therefore, the growing incidence of snake bites is driving the growth of the antivenom industry.

Key Players In The Global Antivenom Market

Major companies operating in the antivenom market are Commonwealth Serum Laboratories, Incepta Pharmaceuticals Limited, Bharat Serums and Vaccines Limited, Rare Disease Therapeutics Inc., Vins Bioproducts Limited, Haffkine Bio-Pharmaceutical Corporation Limited, MicroPharm Limited, Latoxan SAS, Serum Institute of India Pvt. Ltd., BSV Group, Shanghai Serum Biotech Co Ltd., South African Vaccine Producers, Bioclon Institute, Inosan Biopharma, Instituto Bioclon S.A. de C.V., Protherics Inc., Sanofi Pasteur SA, Instituto Clodomiro Picado, Laboratorios Silanes S.A. de C.V., Instituto Biológico Argentino S.A., Instituto Vital Brazil, Instituto Butantan, Instituto Nacional de Producción de Biológicos, Instituto de Biotecnología de la UNAM

Global Antivenom Market Trends and Insights

Major companies operating in the antivenom market are developing advanced technology, such as public-benefit target products, to enhance the efficacy, safety, and accessibility of antivenoms, ultimately aiming to improve patient outcomes and reduce the global burden of snakebite envenomation. Public-benefit target products are healthcare innovations or medical products developed with the primary goal of addressing specific public health needs, particularly in underserved or vulnerable populations. For instance, in June 2023, Bharat Serums and Vaccines Ltd., a US-based biopharmaceutical company, in partnership with the Indian Institute of Science, an India-based public institution to develop region-specific antivenoms for snakebites in India. The collaboration aims to improve treatment effectiveness and reduce the public health impact of snakebites in affected regions.

What Are Latest Mergers And Acquisitions In The Antivenom Market?

In June 2024, MicroPharm Limited, a UK-based pharmaceutical company, announced the acquisition of Sanofi Pasteur for an undisclosed amount. The acquisition aims to expand MicroPharm's portfolio of vaccine products and strengthen its capabilities in research and development. Sanofi Pasteur is a France-based global pharmaceutical company specializing in the research, development, manufacturing, and distribution of vaccines and biological products, including antivenoms.

Regional Insights

North America was the largest region in the global antivenom market size in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antivenom Market?

The antivenom market consists of sales of taipan antivenom and death adder antivenom. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antivenom Market Report 2026?

The antivenom market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antivenom industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.